Immunology and Radiotherapy

Cancer Pharmacology

Discovering the cellular and molecular causes of cancer, as well as identifying and creating new anti-cancer targets and treatment approaches, are the main goals of pharmacology. Our work creates a link between the disciplines of radiation biology, clinical pharmacology, biochemical pharmacology, and molecular carcinogenesis. The Roget Cancer Center, an NCI-designated comprehensive cancer centre, and the Pharmacology Department work closely together on our research activities.

Genetic and epigenetic processes that result in neoplastic transformation characterise the pathologic state known as cancer. Inadequate diagnosis, poor prognosis causing recurrence, and anticancer drug resistance to existing treatment regimens are the main obstacles to cancer prevention and treatment. However, it is extremely difficult for medications to target important pathways that are unique to cancer cells, which has led to low potency, poor target or isoform or kinase selectivity by the present pharmaceuticals or molecules in clinical trials. Off-target effects are also extremely challenging to ignore due to most existing medicines' poor pharmacokinetics and low durability.